Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel antibody-drug conjugates (ADCs) aimed at addressing unmet needs in cancer treatment. Its proprietary technology platforms—Dolasynthen and Immunosynthen—enable the creation of ADCs with cytotoxic and immunostimulatory payloads designed to improve efficacy and tolerability over earlier generations. The company’s clinical pipeline features candidates like Emi-Le (XMT-1660), which targets B7-H4, and XMT-2056, focused on a novel epitope of human epidermal growth factor receptor 2 (HER2), both in Phase 1 trials. Collaborations with major biopharmaceutical firms support its research and development efforts. Based in Cambridge, Massachusetts, Mersana contributes to oncology by advancing targeted therapies that combine antibodies with potent drugs to selectively attack cancer cells while minimizing systemic toxicity, thereby playing a significant role in the innovation landscape of cancer therapeutics.